New Horizons in ESR1-Mutated Breast Cancer
December 10, 2025 • ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment landscape, and the importance of biomarker-driven care. Dr Jhaveri discusses how emerging therapies, especially oral SERDs such as imlunestrant, are transforming treatment for ER+, HER2-, ESR1-mutated breast cancer, offering more effective and convenient options than traditional endocrine therapies. She emphasizes the growing importance of repeat (eg, liquid-biopsy) ESR1 mutation testing to guide therapy as tumors evolve, and highlights ongoing advances aiming to improve outcomes for patients whose cancers acquire resistance.
